Medicure To Webcast Cardiovascular Symposium in New York.

WINNIPEG, Manitoba -- Medicure Inc. (AMEX:MCU) (TSX:MPH), a cardiovascular drug discovery and development company, is pleased to announce that it will webcast its Cardiovascular Symposium: "Emerging Strategies For Saving Your Heart" being held in New York City at the Four Seasons Hotel on Wednesday, October 13, 2004.

To access the live audio webcast of the Symposium, go to the Medicure website at www.medicureinc.com, then click on the link found on the home page:

http://events.onlinebroadcasting.com/medicure/101304

The Medicure-sponsored symposium will bring together four leading experts, seasoned in the science and clinical treatment of cardiovascular disease. They will address the serious medical repercussions of ischemic reperfusions injury leading to acute coronary syndromes, Coronary Artery Bypass Surgery (CABG) and other cardiovascular interventions. In addition, there will be a discussion on the current state of medicine in the field of cardiology and the future therapeutic arsenal for treatment of this deadly disease, with a special focus on Medicure's novel approach to protecting the ischemic myocardium.

"We are delighted and honoured to have such distinguished members of the cardiovascular community participate in this symposium," stated Medicure President & CEO, Dr. Albert Friesen. "This is a very special event for Medicure and I know those in attendance and listening on the webcast will find it informative and interesting."

About the Panel Members

Paul W. Armstrong, MD, FRCP (C), FACC 

Professor and Chair, Department of Medicine, University of Alberta & Chair, Medicure Inc. Scientific Advisory Board

Dr. Armstrong, Chair of Medicure's Scientific Advisory Board, is Professor of Medicine, at the University of Alberta in Edmonton. Dr. Armstrong is an internationally recognized cardiologist and clinical investigator with extensive expertise in the design and conduct of clinical trials focused on acute ischemic syndromes and congestive heart failure. Dr. Armstrong has published widely and served as a senior advisor to major organizations and industry, including Past Member of the US Food and Drug Administration's Cardiovascular and Renal Drug Advisory Committee.

Roberto Bolli, MD, FACC

Chief, Division of Cardiology, Professor of Medicine, Physiology & Biophysics, University of Louisville 

Dr. Bolli is director of the Division of Cardiology at the University of Louisville's Institute for Molecular Cardiology. He earned his medical degree at the University of Perugia in Italy and was a cardiology research fellow at the NIH. Prior to joining U of L, he was Professor of Cardiology at the Baylor College of Medicine in Houston. His research focuses on preventing the damage caused during heart attacks by studying such phenomena as late ischemic preconditioning, in which heart muscle exposed to brief periods of stress becomes resistant to the tissue death that might be caused by a heart attack. He is chair-elect of the AHA's Council on Basic Cardiovascular Sciences, a member of the NIH's program project committee and secretary general of the ISHR.

Christopher Granger, MD, FACC

Associate Professor of Medicine, Duke University Medical Center & Director, Cardiology Site Coordination, Duke Clinical Research Institute

Dr. Chris Granger has been affiliated with the DCRI since 1990. He is the Director of the Duke Cardiology Site Coordination Group, which enrolls cardiology patients in the Duke University Health System in clinical trials. He also is an Associate Professor of Medicine and is also the Director of the Cardiac Care Unit at Duke. Dr. Granger is Associate Editor of the American Heart Journal and serves on the editorial board of the European Heart Journal. He is also a fellow of the American College of Cardiology and the European Society of Cardiology. Dr. Granger has helped lead some of the most important cardiology trials of the last decade, including the GUSTO, ASSENT, and CHARM trials.

Robert A. Harrington, MD, FACC, FSCAI

Professor of Medicine, Duke University Medical Center & Director, Cardiovascular Clinical Trials, Duke Clinical Research Institute

Dr. Harrington has been head of the DCRI's Cardiovascular Clinical Trials division since 1999. He has helped design and lead some of the largest cardiology trials of the past several years, including PURSUIT, PARAGON-A, and PARAGON-B. Before becoming a Professor of Medicine at Duke University Medical Center, Dr. Harrington taught at the University of Massachusetts Medical Center, where he was selected as an Outstanding Medical Educator. He is a Fellow of the American College of Cardiology and of the Society for Cardiovascular Angiography and Intervention, as well as an Associate Editor of the American Heart Journal. Dr. Harrington's clinical and research interests are interventional cardiology, ischemic heart disease, acute coronary care, and cardiovascular clinical trial methods.

About Medicure Inc.

Medicure Inc. is a cardiovascular drug discovery and development Company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine. In its successful Phase II clinical trial, MEND-1, the Company's lead drug, MC-1, demonstrated cardioprotective effects and safety in high-risk patients undergoing angioplasty. The results from this clinical trial showed that MC-1 significantly reduces ischemic heart damage associated with the angioplasty procedure. Proceeding from this positive outcome, Medicure's ongoing Phase II/III MEND-CABG clinical trial is evaluating the cardioprotective and neuroprotective effects of MC-1 in patients undergoing high-risk Coronary Artery Bypass Graft (CABG) surgery. The cardiovascular market is the largest pharmaceutical sector with annual global sales of over US $70 billion.

The Company's second product candidate, MC-4232, is a unique combination drug for the treatment of diabetic patients with hypertension. The co-existing conditions of diabetes and hypertension present a major increase in risk of cardiovascular complications, including coronary artery disease, peripheral artery disease, retinopathy, nephropathy and stroke. MC-4232 is a novel combination product that combines MC-1's cardioprotective properties with an ACE Inhibitor, the most common form of hypertensive therapy. In addition to cardioprotection, this product has also demonstrated potential to provide further blood pressure lowering effects and reduction in glycated hemoglobin (HbA1c), the primary measure of blood glucose control. The Company is currently enrolling patients in the Phase II MATCHED study (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics), evaluating the effects of MC-1 alone and in combination with an ACE Inhibitor in control of blood pressure, metabolism and other endpoints in diabetic patients with hypertension.

Medicure also has a medicinal chemistry based Drug Discovery program focused on discovery and advancement of novel small molecule, anti-ischemics and anti-thrombotics towards human clinical studies.

This press release contains forward-looking statements that involve risks, which may cause actual results to differ materially from the statements made, and accordingly may be deemed to be forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.